Some PARP-related proteins are in a B aggressive lymphoma (BAL) protein family, which are highly expressed in certain types of B cell lymphomas – malignancies of the antibody-producing B lymphocytes.
Sung Hoon Cho, Ph.D., Mark Boothby, M.D., Ph.D., and colleagues, in a collaboration with Christine Eischen, Ph.D., and Owen McGuinness, Ph.D., have discovered that the BAL-family protein PARP14 is vital to interleukin-4 regulation of glycolysis (a metabolic pathway whose activity is commonly increased in cancer), and influences the oncogenic and developmental effect of the Myc pathway.
The results, reported in the Sept. 20 Proceedings of the National Academy of Sciences, suggest that PARP-14’s ability to increase cellular metabolic rates may play a role in the susceptibility to B cell lymphomas. The findings also point to such metabolic pathways as potential targets for treating these types of malignancies.
The research was supported by grants from the National Cancer Institute, the National Institute of General Medical Sciences, and the National Institute of Diabetes and Digestive and Kidney Diseases.